Showing 1 - 9 results of 9 for search 'P. Rossing', query time: 0.03s Refine Results
  1. 1
    P5.18 CENTRAL HEMODYNAMIC’ S ARE ASSOCIATED WITH DIABETIC COMPLICATIONS IN TYPE 1 DIABETES

    P5.18 CENTRAL HEMODYNAMIC’ S ARE ASSOCIATED WITH DIABETIC COMPLICATIONS IN TYPE 1 DIABETES by S. Theilade, T.W. Hansen, P. Rossing

    Published 2013-11-01
    Get full text
    Article
  2. 2
    P3.3 CARDIAC 82RB-PET/CT REVEALS MICROVASCULAR DYSFUNCTION IN ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES

    P3.3 CARDIAC 82RB-PET/CT REVEALS MICROVASCULAR DYSFUNCTION IN ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES by T. Hansen, B. Scholten, P. Hasbak, T. Christensen, A. Ghotbi, A. Kjaer, P. Rossing

    Published 2014-11-01
    Get full text
    Article
  3. 3
    iLearning: The future of higher education? Student perceptions on learning with mobile tablets

    iLearning: The future of higher education? Student perceptions on learning with mobile tablets by Jonathan P. Rossing, Willie M. Miller, Amanda K. Cecil, Suzan E. Stamper

    Published 2012-06-01
    Get full text
    Article
  4. 4
    6.1 LOW-GRADE INFLAMMATION AND ENDOTHELIAL DYSFUNCTION PRECEDE THE INCREASE IN PULSE PRESSURE IN TYPE 1 DIABETES:A 20-YEAR LONGITUDINAL STUDY

    6.1 LOW-GRADE INFLAMMATION AND ENDOTHELIAL DYSFUNCTION PRECEDE THE INCREASE IN PULSE PRESSURE IN TYPE 1 DIABETES:A 20-YEAR LONGITUDINAL STUDY by I. Ferreira, P. Hovind, C.G. Schalkwijk, H.-H. Parving, P. Rossing, C.D.A. Stehouwer

    Published 2009-12-01
    Get full text
    Article
  5. 5
    Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study

    Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study by S. A. Peeters, L. Engelen, J. Buijs, A. Jorsal, H.-H. Parving, L. Tarnow, P. Rossing, C. G. Schalkwijk, C. D. A. Stehouwer

    Published 2017-04-01
    Get full text
    Article
  6. 6
    POS-829 Incidence and predictors of hyperkalaemia in patients with CKD and T2D in the FIDELIO-DKD trial

    POS-829 Incidence and predictors of hyperkalaemia in patients with CKD and T2D in the FIDELIO-DKD trial by R. Agarwal, A. Joseph, P. Rossing, B. Pitt, S. Anker D, G. Filippatos, L. Ruilope M, P. Kolkhof, C. Scott, R. Lawatscheck, G. Bakris L

    Published 2021-04-01
    Get full text
    Article
  7. 7
    P11.03 PULSE PRESSURE PARTIALLY EXPLAINS THE INCREASED INCIDENT CARDIOVASCULAR DISEASE ASSOCIATED WITH INFLAMMATION IN TYPE 1 DIABETES: A 12-YR FOLLOW-UP STUDY

    P11.03 PULSE PRESSURE PARTIALLY EXPLAINS THE INCREASED INCIDENT CARDIOVASCULAR DISEASE ASSOCIATED WITH INFLAMMATION IN TYPE 1 DIABETES: A 12-YR FOLLOW-UP STUDY by J.W.M. Nin, A. Jorsal, I. Ferreira, C.G. Schalkwijk, M.H. Prins, H.-H. Parving, L. Tarnow, P. Rossing, C.D.A. Stehouwer

    Published 2010-12-01
    Get full text
    Article
  8. 8
    POS-831 THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH eGFR <30 mL/min/1.73m2: FINDINGS FROM THE DAPA-CKD TRIAL

    POS-831 THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH eGFR <30 mL/min/1.73m2: FINDINGS FROM THE DAPA-CKD TRIAL by G.M. Chertow, P. Vart, N. Jongs, R.D. Toto, J.L. Gorriz, F.F. Hou, J.J.V. McMurray, R. Correa-Rotter, P. Rossing, C.D. Sjöström, B.V. Stefánsson, A.M. Langkilde, D.C. Wheeler, H. Lambers Heerspink

    Published 2021-04-01
    Get full text
    Article
  9. 9
    POS-832 DAPAGLIFLOZIN IN IgA NEPHROPATHY: FINDINGS FROM THE DAPA-CKD TRIAL

    POS-832 DAPAGLIFLOZIN IN IgA NEPHROPATHY: FINDINGS FROM THE DAPA-CKD TRIAL by H. Lambers Heerspink, R.D. Toto, N. Jongs, P. Vart, G.M. Chertow, F.F. Hou, J.J.V. McMurray, R. Pecoits-Filho, R. Correa-Rotter, P. Rossing, C.D. Sjöström, B.V. Stefánsson, K. Umanath, A.M. Langkilde, D.C. Wheeler

    Published 2021-04-01
    Get full text
    Article

Search Tools: